<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35367280</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-9096</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>202</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Antiviral research</Title>
          <ISOAbbreviation>Antiviral Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The calcium channel inhibitor lacidipine inhibits Zika virus replication in neural progenitor cells.</ArticleTitle>
        <Pagination>
          <StartPage>105313</StartPage>
          <MedlinePgn>105313</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2022.105313</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0166-3542(22)00082-1</ELocationID>
        <Abstract>
          <AbstractText>After decades of being considered non-pathogenic, Zika virus (ZIKV) emerged as an important threat to human health during the epidemic of 2015-2016. ZIKV infections are usually asymptomatic, but can cause Guillain-Barré syndrome in adults and microcephaly in newborns. As there are currently no approved antiviral drugs against ZIKV, we tested anti-ZIKV activity of compounds from the NIH Clinical Collection for which we previously showed antiviral activity against the related dengue virus. One of the top hits from the screen was lacidipine, a 1,4-dihydropyridine calcium antagonist that is approved as an antihypertensive drug. Our data show that lacidipine is antiviral against ZIKV (strain H/PF/2013) in both Vero cells and induced pluripotent stem cell (iPSC)-derived human neural progenitor cells with IC<sub>50</sub> values of 3.0 μM and &lt;50 nM, respectively. The antiviral effect was also observed against four other ZIKV strains from the African and Asian lineages. Time-of-addition and replicon assays indicated that lacidipine acts at the post-entry stage of the viral replication cycle, inhibiting viral genome replication. Lacidipine altered the subcellular distribution of free cholesterol and neutral lipids, suggesting that the antiviral effect of lacidipine is mediated by altered trafficking of lipids. Together, these results identify lacidipine as a novel inhibitor of ZIKV replication that likely disturbs trafficking of lipids needed for replication organelle formation.</AbstractText>
          <CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bezemer</LastName>
            <ForeName>Bodine</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Microbiology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, P.O. Box 9101, 6500 HB, Nijmegen, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Cleef</LastName>
            <ForeName>Koen W R</ForeName>
            <Initials>KWR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Microbiology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, P.O. Box 9101, 6500 HB, Nijmegen, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Overheul</LastName>
            <ForeName>Gijs J</ForeName>
            <Initials>GJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Microbiology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, P.O. Box 9101, 6500 HB, Nijmegen, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miesen</LastName>
            <ForeName>Pascal</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Microbiology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, P.O. Box 9101, 6500 HB, Nijmegen, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Rij</LastName>
            <ForeName>Ronald P</ForeName>
            <Initials>RP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Microbiology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, P.O. Box 9101, 6500 HB, Nijmegen, the Netherlands. Electronic address: ronald.vanrij@radboudumc.nl.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>31</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Antiviral Res</MedlineTA>
        <NlmUniqueID>8109699</NlmUniqueID>
        <ISSNLinking>0166-3542</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015220">Calcium Channels</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004095">Dihydropyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008055">Lipids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>260080034N</RegistryNumber>
          <NameOfSubstance UI="C060285">lacidipine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002121" MajorTopicYN="Y">Calcium Channel Blockers</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015220" MajorTopicYN="N">Calcium Channels</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004095" MajorTopicYN="Y">Dihydropyridines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058953" MajorTopicYN="Y">Neural Stem Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071244" MajorTopicYN="N">Zika Virus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071243" MajorTopicYN="Y">Zika Virus Infection</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Antiviral drugs</Keyword>
        <Keyword MajorTopicYN="N">Cholesterol transport</Keyword>
        <Keyword MajorTopicYN="N">Dengue virus</Keyword>
        <Keyword MajorTopicYN="N">Lacidipine</Keyword>
        <Keyword MajorTopicYN="N">Zika virus</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>3</Day>
          <Hour>20</Hour>
          <Minute>24</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35367280</ArticleId>
        <ArticleId IdType="doi">10.1016/j.antiviral.2022.105313</ArticleId>
        <ArticleId IdType="pii">S0166-3542(22)00082-1</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
